Vaccinex shares are trading lower. The company announced results of its early stage SIGNAL-AD clinical trial of pepinemab antibody in AD.
Portfolio Pulse from Benzinga Newsdesk
Vaccinex shares are trading lower after the company announced results of its early stage SIGNAL-AD clinical trial of pepinemab antibody in Alzheimer's Disease (AD).
July 31, 2024 | 6:58 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Vaccinex shares are trading lower following the announcement of early stage SIGNAL-AD clinical trial results for its pepinemab antibody in Alzheimer's Disease.
The announcement of clinical trial results is a significant event for biotech companies. The market's negative reaction suggests that the results may not have met investor expectations, leading to a decline in share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100